FDA OKs IncobotulinumtoxinA (Xeomin) First-Line in Blepharospasm FDA OKs IncobotulinumtoxinA (Xeomin) First-Line in Blepharospasm

The FDA has approved broadening the indication for incobotulinumbtoxinA as first-line therapy for blepharospasm, based on a phase 3 trial presented at the recent American Academy of Neurology meeting.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news